Ultromics Funding Round Will Support AI-Enabled Echocardiography in Cardiac Disease Treatment

August 16, 2021––Ultromics, a company focused on artificial intelligence- (AI-) enabled cardiovascular imaging solutions, announced that it has raised $33 million in a Series B financing round. The company will use the new funding to accelerate the use of AI-enabled echocardiograms.

Ultromics, which was founded in 2017, has developed a fully automated solution for echocardiography and analysis of global longitudinal strain. Ultromics delivers analysis to any vendor within minutes, with zero variability, without any disruption to workflow, and can predict a patient’s risk of developing coronary artery disease (CAD), stated the company.

According to the company, Ultromics automated software-as-a-service platform is powered by AI to allows clinicians to make fast and accurate decisions when using ultrasound images to diagnose cardiovascular disease.

The EchoGo Core and EchoGo Pro platforms quickly deliver highly accurate assessments of heart function that support the diagnosis of CAD, heart failure, and amyloidosis. Both platforms were spun out of the University of Oxford in Oxford, United Kingdom, and built-in partnership with the United Kingdom’s National Health Service.

The funding round was led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation. Oxford Sciences Innovation had also supported the launch of the company.

Blue Venture Fund is a collaboration among Blue Cross Blue Shield (BCBS) companies, the Blue Cross Blue Shield Association, and Sandbox, to which 35 BCBS companies have committed over $890 million across four funds.

The company noted that the EchoGo Core platform was featured in a recently published study. The findings demonstrated that Ultromics’ AI-generated echocardiography analysis could provide meaningful predictors of health outcomes, where manual analysis did not. “Echocardiographic Correlates of In-Hospital Death in Patients with Acute COVID-19 Infection: The World Alliance Societies of Echocardiography (WASE-COVID) Study” was published by Ilya Karagodin, MD, et al on August 1 in Journal of the American Society of Echocardiography (2021;34:819-830).